Ratings BioSyent Inc.

Equities

RX

CA0906901081

Market Closed - Toronto S.E. Other stock markets 03:56:54 2024-05-22 pm EDT			5-day change	1st Jan Change
9 ^CAD	0.00%		+9.22%	-2.39%

May. 17	BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 17	BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.

Weaknesses

For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BIOSYENT INC.	-2.39%	76.41M	-	-
ELI LILLY AND COMPANY	+37.74%	723B		C+
NOVO NORDISK A/S	+32.22%	598B		B
JOHNSON & JOHNSON	-2.07%	364B		C+
MERCK & CO., INC.	+20.25%	331B		B-
ABBVIE INC.	+2.99%	288B		C+
ASTRAZENECA PLC	+16.60%	244B		B+
NOVARTIS AG	+9.77%	210B		B-
ROCHE HOLDING AG	-5.15%	208B		A+
AMGEN INC.	+7.43%	169B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes